The sustained release excipients market is largely dominated by local manufactures who are competing on the basis of pricing in the market. The fragmented nature of the market decreases the profitability of the business. However, growing awareness about sustained release excipients and lack of test specificity and sensitivity for sustained release excipients manufactured by local companies have increased the revenue opportunities for the global manufacturers in pharmaceutical excipients.
Companies, such as BASF Corporation, Ashland Global Holdings Inc. and The Dow Chemical Company hold more than 42.8% revenue share in the global sustained release excipients market. The companies operating in the sustained release excipients market are collaborating with local distributors to increase the penetration of their products in the sustained release excipients market.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The prevalence of chronic as well as acute diseases is increasing across the globe. For the treatment of these diseases, doctors prescribe medicines. Medicines usually contain excipients along with the active pharmaceutical ingredients. A huge demand for medicines is witnessed because of increasing prevalence of chronic diseases. They are high in demand in Asia Pacific because of huge volume in this region.
Sustained release excipients release the drug slowly so that it reaches the target site. An excipient can be used in many ways. Due to this fact it is in great demand. Sustained release excipients reduce the indirect cost associated with conventional excipients.
Sustained release formulations are gaining popularity as they help in maintaining patient-safety through reduced number of medicine dosages, but having increased drug efficacy. From a market point of view, reduced doses improve treatment compliance, which could help higher unit sales and so their revenues. Furthermore, from the patient point of view, better therapeutic outcomes are expected due to improved drug tolerance and efficacy leading to lower switching costs and greater physician loyalty.
Principal Consultant
Sustained release excipients service providers are offering their services through retail channels. Increasing innovative collaborative research opportunities in pediatric formulations is being pushed through evolution of new regulations, additional funding opportunities, and increased public-private partnerships.
This has been focused to development of excipients used in all kinds of excipients such as oral solid dosage formulations and liquid pediatric formulation, which are flexible, dispersible and multi-functional. Furthermore, continued prioritization of unmet medical needs in pediatrics is expected to drive demand for these excipients and oral formulations in the forthcoming years.
Substance abuse has high impact on the health of individuals and their families. Prolonged drug and alcohol abuse may lead to mental illness and chronic diseases, such as diabetes and heart diseases, cancer, which in turn, can create high economic burden on the society. In order to curb this economic burden caused by drug abuse, governments are focusing on prevention and early intervention strategies are expected to drive demand for drugs of abuse.
For instance, according to the Centers for Disease Control and Prevention (CDC), nearly 10 million individuals aged 55 and above were reported to seek treatment for cancer across the globe. in 2014. Moreover, it is estimated that nearly US$ 600 Bn is spent on addressing the impact caused by substance abuse each year in the U.S.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Competition section of the sustained release excipients market features profiles of key players operating in the industry based on their market shares, differential strategies, product offerings, marketing approach and company dashboard. Examples of some of the key players featured in this report include FMC Corporation, Ashland Global Holdings, BASF Corporation, The Dow Chemical Company, Roquette Freres S.A. Colorcon Inc., Croda International Inc.
The key manufacturers of sustained release excipients are focusing on novel marketing strategies to increase product penetration. The companies offering point-of-care sustained release excipients are concentrating on price floor strategies.
These companies are offering their products with lucrative discounts. Conventional distribution channels, such as retail pharmacies, drug stores, supermarkets and hypermarkets are expected to be the key targets channel for local manufacturers.
The sustained release excipients are one of the type of excipients that are added to the drug along with active pharmaceutical ingredients of medication. Sustained release excipients are pharmacologically non-active ingredients of the drug formulation.
The report offers a comprehensive evaluation of the business opportunities prevailing in the sustained release excipients market along with insights on the sustained release excipients consumption trend, disease incidences, and awareness level for sustained release excipients and sustained release excipients market competition. The report elaborates on the macroeconomic factors influencing the dynamics of sustained release excipients market and its futuristic potential.
Some of the additional questions addressed in this report on sustained release excipients market-
The sustained release excipients market has been estimated based on supply-demand approach. The market was first calculated based on allergy test volume conducted in different region/countries. The test volume was estimated based on the incidence rate of various types of allergies in the top 20 countries globally. Other qualitative factors analyzed during test volume estimation include awareness level for point care sustained release excipients, the recurrence rate of allergy reaction and others.
This information is further validated with rigorous primary research (including interviews, surveys, in-person interactions, and viewpoints of seasoned analysts) and secondary research (including verified paid sources, authentic trade journals, and resourceful databases).
The research study on sustained release excipients market also includes top trends and macro as well as microeconomic factors shaping the sustained release excipients market. With this approach, the report on sustained release excipients market anticipates the industry attractiveness of every major segment in sustained release excipients market over the forecast period.
The report offers a comprehensive taxonomy of sustained release excipients market based on product type, end user, route of administration route, and region. The sustained release excipients are sold for various types of test samples, such as blood, skin, etc. These sustained release excipients are used by pharmaceutical companies, biopharmaceutical companies, neutraceutical companies, and for various type of sustained release excipients, such as food allergies, drug allergies, latex allergies and other types of allergies.
End-use segments in the sustained release excipients market which are a part of this sustained release excipients market report include pharmaceutical companies, biopharmaceutical companies and other end users, such as nutraceutical manufacturers and contract manufacturing organisations. The sustained release excipients market has been analyzed across regions of North America, Latin America, Europe, CIS & Russia, Asia Pacific and MEA.
Demand for sustained release excipients is likely to grow at a CAGR of 7.5% through 2032.
Increased benefits over conventional dosage forms and antibiotic resistance.
Adoption of sustained release excipients is likely to reach a valuation of US$ 1198.69 Mn in 2022
FMC Corporation, Ashland Global Holdings, BASF Corporation, The Dow Chemical Company, Roquette Freres S.A. Colorcon Inc., and Croda International Inc.
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Definition
2.2. Market Structure
3. Market Opportunity Analysis
4. Market Analysis Scenario
4.1. Macro-Economic Factors
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
4.2.4. Opportunity Analysis
5. Global Economic Outlook
6. North America Market Analysis and Forecast
6.1. Introduction
6.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2017
6.2.1. U.S.
6.2.2. Canada
6.3. Market Value (US$ Mn) Forecast By Country, 2018-2026
6.4. Historical Market Value (US$ Mn) Analysis By Excipient type, 2013-2017
6.4.1. Gelatin
6.4.2. Polymers
6.4.3. Minerals
6.4.4. Sugars
6.4.5. Alcohol
6.4.6. Chitosan
6.5. Market Value (US$ Mn) Forecast By Excipient type, 2018-2026
6.6. Historical Market Value (US$ Mn) Analysis By Route of Administration, 2013-2017
6.6.1. Oral
6.6.2. Injectable
6.6.3. Vaginal
6.6.4. Ophthalmic
6.7. Market Value (US$ Mn) Forecast By Route of Administration, 2018-2026
6.8. Historical Market Value (US$ Mn) Analysis By Distribution Channels, 2013-2017
6.8.1. Pharmaceutical Companies
6.8.2. Biopharmaceutical Companies
6.8.3. Nutraceutical Manufacturers
6.8.4. Contract Manufacturing Organizations
6.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2018-2026
6.10. Drivers and Restraints: Impact Analysis
6.11. Market Attractiveness Analysis
6.11.1. By Country
6.11.2. By Excipient type
6.11.3. By Route of Administration
6.11.4. By Distribution Channels
7. Latin America Market Analysis and Forecast
7.1. Introduction
7.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2017
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Market Value (US$ Mn) Forecast By Country, 2018-2026
7.4. Historical Market Value (US$ Mn) Analysis By Excipient type, 2013-2017
7.4.1. Gelatin
7.4.2. Polymers
7.4.3. Minerals
7.4.4. Sugars
7.4.5. Alcohol
7.4.6. Chitosan
7.5. Market Value (US$ Mn) Forecast By Excipient type, 2018-2026
7.6. Historical Market Value (US$ Mn) Analysis By Route of Administration, 2013-2017
7.6.1. Oral
7.6.2. Injectable
7.6.3. Vaginal
7.6.4. Ophthalmic
7.7. Market Value (US$ Mn) Forecast By Route of Administration, 2018-2026
7.8. Historical Market Value (US$ Mn) Analysis By Distribution Channels, 2013-2017
7.8.1. Pharmaceutical Companies
7.8.2. Biopharmaceutical Companies
7.8.3. Nutraceutical Manufacturers
7.8.4. Contract Manufacturing Organizations
7.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2018-2026
7.10. Drivers and Restraints: Impact Analysis
7.11. Market Attractiveness Analysis
7.11.1. By Country
7.11.2. By Excipient type
7.11.3. By Route of Administration
7.11.4. By Distribution Channels
8. Europe Market Analysis and Forecast
8.1. Introduction
8.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2017
8.2.1. Germany
8.2.2. France
8.2.3. U.K.
8.2.4. Spain
8.2.5. Italy
8.2.6. Rest of Europe
8.3. Market Value (US$ Mn) Forecast By Country, 2018-2026
8.4. Historical Market Value (US$ Mn) Analysis By Excipient type, 2013-2017
8.4.1. Gelatin
8.4.2. Polymers
8.4.3. Minerals
8.4.4. Sugars
8.4.5. Alcohol
8.4.6. Chitosan
8.5. Market Value (US$ Mn) Forecast By Excipient type, 2018-2026
8.6. Historical Market Value (US$ Mn) Analysis By Route of Administration, 2013-2017
8.6.1. Oral
8.6.2. Injectable
8.6.3. Vaginal
8.6.4. Ophthalmic
8.7. Market Value (US$ Mn) Forecast By Route of Administration, 2018-2026
8.8. Historical Market Value (US$ Mn) Analysis By Distribution Channels, 2013-2017
8.8.1. Pharmaceutical Companies
8.8.2. Biopharmaceutical Companies
8.8.3. Nutraceutical Manufacturers
8.8.4. Contract Manufacturing Organizations
8.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2018-2026
8.10. Drivers and Restraints: Impact Analysis
8.11. Market Attractiveness Analysis
8.11.1. By Country
8.11.2. By Excipient type
8.11.3. By Route of Administration
8.11.4. By Distribution Channels
9. CIS & Russia Market Analysis and Forecast
9.1. Introduction
9.2. Historical Market Value (US$ Mn) Analysis By Excipient type, 2013-2017
9.2.1. Gelatin
9.2.2. Polymers
9.2.3. Minerals
9.2.4. Sugars
9.2.5. Alcohol
9.2.6. Chitosan
9.3. Market Value (US$ Mn) Forecast By Excipient type, 2018-2026
9.4. Historical Market Value (US$ Mn) Analysis By Route of Administration, 2013-2017
9.4.1. Oral
9.4.2. Injectable
9.4.3. Vaginal
9.4.4. Ophthalmic
9.5. Market Value (US$ Mn) Forecast By Route of Administration, 2018-2026
9.6. Historical Market Value (US$ Mn) Analysis By Distribution Channels, 2013-2017
9.6.1. Pharmaceutical Companies
9.6.2. Biopharmaceutical Companies
9.6.3. Nutraceutical Manufacturers
9.6.4. Contract Manufacturing Organizations
9.7. Market Value (US$ Mn) Forecast By Distribution Channels, 2018-2026
9.8. Drivers and Restraints: Impact Analysis
9.9. Market Attractiveness Analysis
9.9.1. By Country
9.9.2. By Excipient type
9.9.3. By Route of Administration
9.9.4. By Distribution Channels
10. Asia Pacific Market Analysis and Forecast
10.1. Introduction
10.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2017
10.2.1. China
10.2.2. India
10.2.3. ASEAN
10.2.4. Australia and New Zealand
10.2.5. Rest of APEJ
10.3. Market Value (US$ Mn) Forecast By Country, 2018-2026
10.4. Historical Market Value (US$ Mn) Analysis By Excipient type, 2013-2017
10.4.1. Gelatin
10.4.2. Polymers
10.4.3. Minerals
10.4.4. Sugars
10.4.5. Alcohol
10.4.6. Chitosan
10.5. Market Value (US$ Mn) Forecast By Excipient type, 2018-2026
10.6. Historical Market Value (US$ Mn) Analysis By Route of Administration, 2013-2017
10.6.1. Oral
10.6.2. Injectable
10.6.3. Vaginal
10.6.4. Ophthalmic
10.7. Market Value (US$ Mn) Forecast By Route of Administration, 2018-2026
10.8. Historical Market Value (US$ Mn) Analysis By Distribution Channels, 2013-2017
10.8.1. Pharmaceutical Companies
10.8.2. Biopharmaceutical Companies
10.8.3. Nutraceutical Manufacturers
10.8.4. Contract Manufacturing Organizations
10.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2018-2026
10.10. Drivers and Restraints: Impact Analysis
10.11. Market Attractiveness Analysis
10.11.1. By Country
10.11.2. By Excipient type
10.11.3. By Route of Administration
10.11.4. By Distribution Channels
11. MEA Market Analysis and Forecast
11.1. Introduction
11.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2017
11.2.1. GCC Countries
11.2.2. South Africa
11.2.3. Rest of MEA
11.3. Market Value (US$ Mn) Forecast By Country, 2018-2026
11.4. Historical Market Value (US$ Mn) Analysis By Excipient type, 2013-2017
11.4.1. Gelatin
11.4.2. Polymers
11.4.3. Minerals
11.4.4. Sugars
11.4.5. Alcohol
11.4.6. Chitosan
11.5. Market Value (US$ Mn) Forecast By Excipient type, 2018-2026
11.6. Historical Market Value (US$ Mn) Analysis By Route of Administration, 2013-2017
11.6.1. Oral
11.6.2. Injectable
11.6.3. Vaginal
11.6.4. Ophthalmic
11.7. Market Value (US$ Mn) Forecast By Route of Administration, 2018-2026
11.8. Historical Market Value (US$ Mn) Analysis By Distribution Channels, 2013-2017
11.8.1. Pharmaceutical Companies
11.8.2. Biopharmaceutical Companies
11.8.3. Nutraceutical Manufacturers
11.8.4. Contract Manufacturing Organizations
11.9. Market Value (US$ Mn) Forecast By Distribution Channels, 2018-2026
11.10. Drivers and Restraints: Impact Analysis
11.11. Market Attractiveness Analysis
11.11.1. By Country
11.11.2. By Excipient type
11.11.3. By Route of Administration
11.11.4. By Distribution Channels
12. Forecast Factors: Relevance and Impact
13. Forecast Assumptions
14. Market Structure Analysis
14.1. Market Structure by Tier
14.2. Market Share Analysis (2017) for Top Players
14.3. Product Intensity Mapping by Key Manufacturer
15. Competition Landscape
15.1. Competition Dashboard
15.2. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
15.2.1. BASF Corporation
15.2.2. FMC Corporation
15.2.3. Ashland Global Holdings Inc.
15.2.4. Roquette Freres S.A
15.2.5. Colorcon Inc.
15.2.6. Croda International PLC
15.2.7. The Dow Chemical Company (DowDuPont)
16. Global Market Analysis and Forecast, By Region
16.1.1. A detailed, region-wise assessment, providing projections on market growth in key regions
16.2. Introduction
16.3. Historical Market Value (US$ Mn) Analysis By Region, 2013-2017
16.3.1. North America
16.3.2. Latin America
16.3.3. Western Europe
16.3.4. Eastern Europe
16.3.5. Asia Pacific Excl. CIS & Russia (APEJ)
16.3.6. CIS & Russia
16.3.7. Middle East and Africa (MEA)
16.4. Market Value (US$ Mn) Forecast By Region, 2018-2026
16.5. Market Attractiveness Analysis By Region
17. Global Market Analysis and Forecast, By Excipient type
17.1. Introduction
17.2. Historical Market Value (US$ Mn) Analysis By Excipient type, 2013-2017
17.2.1. Gelatin
17.2.2. Polymers
17.2.3. Minerals
17.2.4. Sugars
17.2.5. Alcohol
17.2.6. Chitosan
17.3. Market Value (US$ Mn) Forecast By Excipient type, 2018-2026
17.4. Market Attractiveness Analysis By Excipient type
18. Global Market Analysis and Forecast, By Route of Administration
18.1. Introduction
18.2. Historical Market Value (US$ Mn) Analysis By Route of Administration, 2013-2017
18.2.1. Oral
18.2.2. Injectable
18.2.3. Vaginal
18.2.4. Ophthalmic
18.3. Market Value (US$ Mn) Forecast By Route of Administration, 2018-2026
18.4. Market Attractiveness Analysis By Route of Administration
19. Global Market Analysis and Forecast, By Distribution Channels
19.1. Introduction
19.2. Historical Market Value (US$ Mn) Analysis By Distribution Channels, 2013-2017
19.2.1. Pharmaceutical Companies
19.2.2. Biopharmaceutical Companies
19.2.3. Nutraceutical Manufacturers
19.2.4. Contract Manufacturing Organizations
19.3. Market Value (US$ Mn) Forecast By Distribution Channels, 2018-2026
19.4. Market Attractiveness Analysis By Distribution Channels
20. Global Market Analysis 2013–2017 and Forecast 2018–2028
20.1. Market Value Share Analysis By All Segment
20.2. Y-o-Y Growth Analysis By All Segment
Explore Healthcare Insights
View Reports
Sustained Release Excipients Market
